$90.59 1.7%
GILD Stock Price vs. AI Score
Data gathered: December 9

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Gilead Sciences (GILD)

Analysis generated September 16, 2024. Powered by Chat GPT.

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative medicines. The company's primary areas of focus include antiviral therapeutics, particularly in the fields of HIV, hepatitis B and C, and influenza. Gilead has a rich portfolio of products and an active pipeline of investigational drugs, positioning itself as a key player in the biopharma industry.

Read full AI stock Analysis

Stock Alerts - Gilead Sciences (GILD)

company logo Gilead Sciences | December 4
Insider Alert: Dickinson Andrew D is selling shares
company logo Gilead Sciences | November 30
Insider Alert: Parsey Merdad is selling shares
company logo Gilead Sciences | November 28
Insider Alert: Bluestone Jeffrey is selling shares
company logo Gilead Sciences | November 27
Job postings are up by 26.4% in the last couple of days.

About Gilead Sciences

Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.


Gilead Sciences
Price $90.59
Target Price Sign up
Volume 7,400,000
Market Cap $115B
Year Range $62.11 - $97.9
Dividend Yield 3.34%
PE Ratio 1023.67
Analyst Rating 58% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '247.54B4.79B2.76B1.25B-191M2.020
Q2 '246.98B2.94B4.04B1.61B3.38B2.010
Q1 '246.46B5.42B1.04B-4.17B2.99B-1.320
Q4 '236.87B5.08B1.79B1.43B2.52B1.720
Q3 '236.82B3.48B3.34B2.18B3.16B2.290

Insider Transactions View All

Dickinson Andrew D filed to sell 266,849 shares at $92.8.
December 3 '24
Dickinson Andrew D filed to sell 138,919 shares at $92.8.
December 3 '24
Parsey Merdad filed to sell 91,200 shares at $91.8.
November 29 '24
Parsey Merdad filed to sell 94,399 shares at $91.8.
November 29 '24
Parsey Merdad filed to sell 80,801 shares at $92.
November 29 '24

Congress Trading View All

Politician Filing Date Type Size
Rohit Khanna
Democrat
Jun 5, 24 Buy $1K - $15K
Thomas Tuberville
Republican
May 15, 24 Buy $1K - $15K
Rohit Khanna
Democrat
May 6, 24 Sell $1K - $15K

What is the Market Cap of Gilead Sciences?

The Market Cap of Gilead Sciences is $115B.

What is Gilead Sciences' PE Ratio?

As of today, Gilead Sciences' PE (Price to Earnings) ratio is 1023.67.

What is the current stock price of Gilead Sciences?

Currently, the price of one share of Gilead Sciences stock is $90.59.

How can I analyze the GILD stock price chart for investment decisions?

The GILD stock price chart above provides a comprehensive visual representation of Gilead Sciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Gilead Sciences shares. Our platform offers an up-to-date GILD stock price chart, along with technical data analysis and alternative data insights.

Does GILD offer dividends to its shareholders?

Yes, Gilead Sciences (GILD) offers dividends to its shareholders, with a dividend yield of 3.34%. This dividend yield represents Gilead Sciences' commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Gilead Sciences in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.

What are some of the similar stocks of Gilead Sciences?

Some of the similar stocks of Gilead Sciences are Amgen, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Anavex Life Sciences, and BridgeBio Pharma.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.